Detailed information for compound 40237

Basic information

Technical information
  • TDR Targets ID: 40237
  • Name: ethyl 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-di methoxyphenyl)-6-oxo-5a,8,8a,9-tetrahydro-5H- [2]benzofuro[6,5-f][1,3]benzodioxol-9-yl]amin o]piperidine-1-carboxylate
  • MW: 554.588 | Formula: C29H34N2O9
  • H donors: 2 H acceptors: 3 LogP: 2.93 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 2
  • SMILES: CCOC(=O)N1CCC(CC1)N[C@H]1[C@H]2COC(=O)[C@@H]2[C@@H](c2c1cc1OCOc1c2)c1cc(OC)c(c(c1)OC)O
  • InChi: 1S/C29H34N2O9/c1-4-37-29(34)31-7-5-16(6-8-31)30-26-18-12-21-20(39-14-40-21)11-17(18)24(25-19(26)13-38-28(25)33)15-9-22(35-2)27(32)23(10-15)36-3/h9-12,16,19,24-26,30,32H,4-8,13-14H2,1-3H3/t19-,24+,25-,26+/m0/s1
  • InChiKey: DUMFAXPMUDPKMH-QNMIOERPSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • ethyl 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxy-phenyl)-6-oxo-5a,8,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-9-yl]amino]piperidine-1-carboxylate
  • 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxyphenyl)-6-oxo-5a,8,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-9-yl]amino]-1-piperidinecarboxylic acid ethyl ester
  • ethyl 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxy-phenyl)-6-oxo-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-9-yl]amino]piperidine-1-carboxylate
  • 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxy-phenyl)-6-keto-5a,8,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-9-yl]amino]piperidine-1-carboxylic acid ethyl ester
  • ethyl 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxy-phenyl)-6-oxo-5a,8,8a,9-tetrahydro-5H-isobenzofurano[6,5-f][1,3]benzodioxol-9-yl]amino]piperidine-1-carboxylate
  • 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxyphenyl)-6-oxo-5a,8,8a,9-tetrahydro-5H-isobenzofurano[6,5-f][1,3]benzodioxol-9-yl]amino]-1-piperidinecarboxylic acid ethyl ester
  • 4-[[(5R,5aR,8aS,9S)-5-(4-hydroxy-3,5-dimethoxy-phenyl)-6-keto-5a,8,8a,9-tetrahydro-5H-isobenzofurano[6,5-f][1,3]benzodioxol-9-yl]amino]piperidine-1-carboxylic acid ethyl ester

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma cruzi squalene synthase, putative 0.9435 0.5 0.5
Trypanosoma brucei squalene synthase, putative 0.9435 0.5 0.5
Trypanosoma cruzi squalene synthase, putative 0.9435 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
Complex formation (binding) = 17 % Percentage of intracellular covalent DNA-topoisomerase II complexes formed ChEMBL. 12014968
Complex formation (functional) = 17 % Percentage inhibition of cellular protein-DNA complex formation ChEMBL. 8120864
Complex formation (binding) = 17 % Percentage of intracellular covalent DNA-topoisomerase II complexes formed ChEMBL. 12014968
GI50 (functional) -6.655 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -6.539 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -6.3 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -6.048 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -5.965 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -5.951 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -5.917 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -5.909 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) ChEMBL. No reference
ID50 (functional) = 0.74 uM Cytotoxicity against KB cells after a 3 day incubation ChEMBL. 8120864
ID50 (functional) = 0.74 uM Cytotoxicity against KB cells after a 3 day incubation ChEMBL. 8120864
ID50 (binding) = 25 uM 50% inhibition of human DNA topoisomerase II ChEMBL. 8120864
ID50 (binding) = 25 uM 50% inhibition of human DNA topoisomerase II ChEMBL. 8120864
Log GI50 (functional) = -5.87 Drug molar concentration required to inhibit 50% of human tumor cell growth ChEMBL. 8120864
Log LC50 (functional) = -4.44 Drug concentration required to cause 50% cell death ChEMBL. 8120864
Log TGI (functional) = -5.11 Drug concentration required to inhibit total cell growth ChEMBL. 8120864
Protein-DNA complex formation (functional) = 17 % Compound tested for ability to form a cellular covalent topoisomerase II-DNA complex. ChEMBL. 8691468
Protein-DNA complex formation (functional) = 17 % Compound tested for ability to form a cellular covalent topoisomerase II-DNA complex. ChEMBL. 8691468

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

3 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.